The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients

Philippe Lucas1,2,3*, Susan Boyd4, M.-J. Milloy5,6 and Zach Walsh7,8

Abstract
Background: Despite repeated calls by medical associations to gather evidence on the harms and benefits of cannabis, there are ongoing methodological challenges to conducting observational and clinical studies on cannabis, including a high rate of patients that are lost to follow-up (LTFU). This study explores factors potentially associated with retention in a large prospective study of Canadian medical cannabis patients, with the goal of reducing the probability that patients will be lost to follow-up in future cannabis research.

Methods: The Tilray Observational Patient Study (TOPS) was a multi-site, prospective study assessing the impact of medical cannabis over 6 months in a broad population of authorized Canadian cannabis patients. The study took place from 2016 to 19, and we conducted a series of exploratory analyses including a Kaplan–Meier survival analysis and logistic regressions to assess the potential association between study retention and variables including patient characteristics, cannabis and prescription drug use, quality of life, and the legalization of non-medical cannabis.

Results: Overall, 1011 participants were included in this analysis, contributing 287 patient-years of data. Retention was 728 (72%) at 3 months, and 419 (41.4%) at 6 months. Our analyses found significantly lower adjusted odds of retention following legalization (AOR 0.28, 95% CI 0.18–0.41), and in patients that used prescription opioids at baseline (AOR 0.62, 95% CI 0.46–0.85), while increased odds of retention were found in patients with a higher baseline psychological score (AOR 1.43, 95% CI 1.08–1.90) or that used anti-seizure medications at baseline (AOR 1.91, 95% CI 1.30–2.81).

Discussion: TOPS provided a unique opportunity to examine patient characteristics and other variables that may be associated with retention in prospective medical cannabis studies. Our findings highlight some of the challenges of conducting medical cannabis research at a time when patients have a multitude of cannabis access options, including legal adult dispensaries and a robust illicit market. High LTFU rates can impact the validity of studies, and potentially lead to misestimations of the harms and benefits of medical cannabis use. Despite being a multi-site prospective...
study, this was a convenience sample, thereby limiting the generalizability of these findings. Additionally, data regarding the use of cannabis was self-reported by patients, so is subject to potential recall bias.

**Conclusion:** We found evidence that external policy changes that affect access to cannabis such as the legalization of non-medical adult use and patient characteristics associated with patient physical/psychological capacity can impact retention in prospective medical cannabis studies. Evidence-based strategies to reduce study burden on participants, such as minimizing in-person visits by providing digitized internet-based surveys and phone or telemedicine follow-up options as well as ensuring adequate participant compensation could improve retention. Additionally, policy-related changes aimed at improving access to medical cannabis, including increased cost-coverage and community-based distribution, could encourage patients to remain in the federal medical cannabis program and thereby reduce LTFU in associated studies.

**Keywords:** Cannabis, Marijuana, Retention, Legalization, Survival analysis, Drop out, Clinical trial

**Background**
In 2001, Canada became one of the first nations to regulate medical cannabis at a federal level, and in 2018 it was the second country to legalize the non-medical use of cannabis by adults (Fischer et al., 2020; Lucas et al., 2019). Despite consistent calls by the Canadian Medical Association and American Medical Association citing the need for high-quality studies to identify the risks and benefits of cannabis in both medical and non-medical applications (Cannabis | CMA Health Topics, 2020; Harris, 2019), there are many historical and ongoing challenges to conducting such research. As a result, many systematic reviews examining the available evidence in a number of primary therapeutic applications for cannabis have cited both a lack of and need for well-designed longitudinal observational and controlled studies (Bonaccorso et al. 2019; Hoch et al. 2019; Kosiba et al., 2019; Okusanya et al. 2020).

There are a number of challenges to conducting high-quality cannabis research in Canada and in other jurisdictions. These include social stigma resulting from the long-standing international prohibition on cannabis possession and use (Belle-Isle et al. 2014; Bottorff et al. 2013; Lucas, 2009), a lack of funding and regulatory obstacles and associated delays National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana, 2017; Geary 2019), and methodological difficulties, such as the inability to blind THC-based products in controlled studies due to its potential for impairment (Russo 2016; National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana, 2017). Additionally, legalizing the adult, non-medical use of cannabis in Canada in October 2018 has significantly changed how medical and non-medical adult users access cannabis, and this may have subsequent impacts on recruitment, adherence, and retention in prospective medical cannabis studies in Canada.

The legalization of the adult non-medical use of cannabis in Canada is in its nascency, and the federal, provincial, and municipal policies governing access continue to evolve. However, some data suggests that one of the impacts of legalization has been a decline in participation in the federal medical cannabis program. Recent statistics from Health Canada show that the number of authorized patients peaked in September 2019 at 369,614 (although legalization took place in October 2018, medical cannabis recommendations by health care practitioners are valid for a maximum of 12 months, so a decline in patient renewals would be staggered accordingly), declining steadily to 303,221 in June 2020, the latest month for which data was available (Health Canada 2020). This steady migration away from the medical cannabis program may be due to a number of factors. Over the years, many barriers have been identified in accessing medical cannabis in Canada, including stigma, lack of support from the medical community, limited product selection, and high costs (Belle-Isle and Hathaway, 2007; Bottorff et al. 2013; Capler et al. 2017; Lucas, 2009). By contrast, both the illicit market as well as the legal, non-medical cannabis dispensaries offer many advantages not currently available in the mail-order only federal medical cannabis program, including the opportunity for in-person, community-based interactions, a large selection of products from hundreds of different producers, and highly competitive pricing. Furthermore, a few studies examining the impact of legalization on patient access to medical cannabis report that product shortages in the medical system immediately following legalization led patients to purchase cannabis from non-medical sources, including the illicit market (McTaggart-Cowan et al. 2020; Hawley 2020).
following legalization could also be affecting retention in prospective medical cannabis studies.

Therefore, we conducted an exploratory analysis of a large prospective study of medical cannabis patients to examine the potential relationship between study retention and respondent characteristics, psychosocial factors, cannabis use, and the use of prescription drugs. Additionally, we examined whether the legalization of non-medical adult cannabis use impacted the rates of patients lost to follow-up (LTFU). Our objectives were to identify factors associated with retention, and to recommend clinical strategies and policy options that might reduce LTFU in future longitudinal medical cannabis studies. Moreover, our findings may prove useful in contextualizing existing findings on the outcomes of cannabis use in other longitudinal studies.

Methods
The Tilray Observational Patient Study (TOPS) was a national, multi-site, prospective medical cannabis study that took place at 21 medical clinics in five Canadian provinces, with the goal of gathering detailed information on patient characteristics and examining the impact of medical cannabis use on quality of life and prescription drug use over 6 months. TOPS used a pre-test/post-test repeated measures design, with data gathering at baseline, 1 month, 3 months, and 6 months. The study was reviewed and approved by Advarra (formerly Institutional Review Board Services) on 22 January 2016, the University of Victoria on 7 April 2016, and the Alberta Health Research Ethics Board of Alberta 3 October 2016, and sponsored by Tilray, a licensed medical cannabis production and research company based in British Columbia, Canada.

Physicians identified, recruited, and screened patients in-clinic during regularly scheduled appointment, guided by ethics-approved Health Care Provider Talking Points provided by the study sponsor (Additional file 1). Participants were federally authorized, English speaking medical cannabis patients 18 years old and over with the capacity to consent for themselves who received a new cannabis recommendation from a participating physician, and subsequently registered with Tilray to obtain their medical cannabis products via mail. As compensation for their time, participants received a $25 credit towards their medical cannabis costs after completing each set of surveys. Clinics and participating physicians were identified and trained in the administration of the study by the principal investigator and colleagues, and data was gathered digitally via REDCap, a secure electronic data capture system (Harris et al. 2019). Study analyses included 1011 participants who enrolled in TOPS before 16 July 2018 to ensure all those included had the opportunity to be in the study at least 6 months and therefore could have completed all study visits.

Measures
TOPS was composed of a combination of validated and novel instruments made up of multiple-choice questions, rating and rankings, visual assessment scales (VAS) and Likert scales, as well as matrix and dropdown questions. Many questions also included an “other” option that then provided a text box for short textual responses. The primary outcome of interest for this analysis was retention in the study at 6 months, and the explanatory variables we hypothesized may be related to retention included primary patient demographics, baseline quality of life scores, and patterns of medical cannabis and prescription drug use, as well as whether patients participated in the study prior to or after the legalization of adults non-medical use of cannabis in Canada on 17 October 2018.

Demographic data (such as age, gender, marital status, education level, employment status, and province of residence) and primary condition were self-reported and gathered via multiple choice questions informed by past longitudinal and cross-sectional surveys (Lucas et al. 2019; Lucas and Walsh, 2017; Walsh et al. 2013). The study included three additional instruments: the World Health Organization Quality of Life Short Form, the Cannabis Use Survey, and the Prescription Drug Questionnaire.

The World Health Organization Quality of Life Short Form (WHOQOL-Bref) (WHOQOL Group, 1998) is a validated 26-item questionnaire derived from data collected using the WHOQOL-100. It produces scores for four domains related to quality of life: physical health, psychological, social relationships, and environment. (Saxena et al. 2001). The Cannabis Use Survey (CUS) is a 17-question self-administered patient questionnaire designed to gather cross-sectional and/or prospective information on medical cannabis patient primary conditions, symptoms, and patterns of medical cannabis use such as amounts used, preferred methods of use, and cannabis type preferences (e.g., THC vs. CBD). The Prescription Drug Questionnaire (PDQ) was designed to produce an accurate inventory of current health care provider authorized prescription drug use by a patient, and is completed by physicians and/or medical clinic staff in cooperation with the patient in order to limit the potential for recall bias. It gathers detailed information on daily and non-daily prescription drug use in milligrams per dose, and doses per day or week (where applicable), and has an auto-fill function connected to the National Drug Data File (NDDF), a US-based national prescription drug
database, to ensure that consistent generic prescription drug names are used across participants and medical clinics in order to facilitate analysis.

This battery was administered at four different time points: at baseline after a patient has received a medical cannabis recommendation from the participating physician, and then at 1 month (M1), 3 months (M3), and 6 months (M6). If a patient missed a study visit, they were nonetheless contacted and given the opportunity to continue with the study at the next time point.

Data analysis

Summary statistics were calculated for the following patient characteristics: age, gender, education level and marital status, as well as for primary condition, and past/present cannabis usage ( naïve vs. non-naïve; method of use; frequency of use). Cannabis-naïve patients were defined as those who had used cannabis four times or fewer in the previous 12 months.

In order to assess quality of life, the four domains of the WHOQOL-Bref were tabulated at each study visit, and mixed-effects linear regression was used to model the time trend of the four domains over the 6-month period for all patients, as well as by different levels of demographic variables and other baseline patient characteristics.

The analysis of prescription drug use data included descriptive summaries of the number and percentage of patients who used each medication stratified by baseline usage of the particular medication, as well as by patient characteristics. To assess the dosage and usage frequency data among those who used the medication at baseline, milligrams (mg) per dose was first converted to milligrams per day by multiplying milligrams per dose with the frequency per day. The reported dosage for each drug was then divided by its defined daily dose (DDD) to facilitate a summary of dosage data across patients (WHO Collaboration Center for Drug Statistics Methodology 2019), and then the most prevalent drugs were grouped into five primary drug classes for further analysis: opioid and non-opioid pain medications, benzodiazepines, antidepressants, and anti-seizure drugs.

As the survival analysis focused on two time points (M3 and M6), the Kaplan–Meier method and log-rank test were used, with the primary outcome of interest being retention at M6. If a patient did not complete both M3 and M6, the patient was considered to be dropped out at M3. If a patient completed M3 visit but not M6, the patient was considered to be dropped out at M6. The completion rate of M6 was initially summarized by patient characteristics, change in QOL, and change in drug usage. In order to facilitate the logistic regression and Kaplan–Meier analysis, we re-defined some measures such as QOL as binary outcomes using the median split of the 1011 patients included in this analysis. The Kaplan–Meier estimator then reported the probability of remaining in the study at M3 and M6, and we used the log-rank test for between group comparisons. Groups with less than five patients were not assessed.

We then proceeded with a univariate logistic regression analysis in order to better understand the association between the variables assessed in the Kaplan–Meier estimator and retention at M6, with the addition of a binary variable to assess potential impact of legalization by comparing retention between patients enrolled prior to 17 April 2018 (so that M6 would be before legalization) and those enrolled between 17 April to 15 July 2018 (so M6 would be post-legalization). This was followed by a multivariate analysis that included all significant variables from the univariate analysis, using a chi-square test for homogeneity.

All analyses were conducted in SAS 9.4 (SAS Institute, Cary, NC, USA) and/or R 3.6.3 (R Core Team). All statistical tests were two-sided, with significance levels of 0.05 unless otherwise indicated.

Results

Overall, 1011 were included in this analysis and contributed 287 patient-years of observation. Retention was 728 (72%) at 3 months, and 419 (41.4%) at 6 months. Tables 1 and 2 provide an overview of the primary baseline characteristics of the 1011 patients included in this analysis, along with the associated percentage that remained in the study at M6, and the results of the Kaplan–Meier estimator probability of remaining in the study at M3 and M6. Most participants were female (578, 57%) and 560 (55%) having at least a college degree. The median age was 51.0 (IQR 38–61) at baseline, and most were married or equivalent (561, 56%). The top 5 primary conditions reported by participants were chronic pain (703, 70%), anxiety disorders (98, 10%), arthritis (63, 6%), insomnia (48, 5%), and headache (23, 2%). Therefore, pain, mental health issues, and insomnia accounted for approximately 94% of all participant primary conditions. These participant characteristics are largely consistent with previous Canadian and international studies of medical cannabis patients (Hazekamp et al. 2013; Baron et al. 2018; Boehnke et al. 2019; Lintzeris et al. 2020). No statistically significant associations were found between patient characteristics such as gender, education, marital status, age, previous cannabis experience, and primary condition and the probability of remaining in the study.

Table 2 highlights the rate of study completion and probability of retention at M3 and M6 by baseline...
prescription drug use and quality of life. Overall, 283 participants were LTFU at M3, and a further 309 were LTFU at M6. The five most commonly used prescription drug classes were opioids, with 290 (29.4%) reporting baseline opioid use, followed by non-opioid pain medications (215, 21.8%), antidepressants (166, 16.9%), anti-seizure drugs (159, 16.1%), and benzodiazepines (67, 6.8%).

Baseline opioid use was associated with lower rates of completion, with 44% of non-opioid users completing M6 ($n = 306$) compared to 35% of opioid users ($n = 102$).

Table 1 Percent completing M6 and probability of retention at M3 and M6 by patient baseline characteristics and primary condition in 1011 participants

| Patient baseline characteristics                  | Completed M6 (%) | Kaplan–Meier estimator |
|---------------------------------------------------|-----------------|------------------------|
|                                                   |                 | Probability of remaining in study |
|                                                   |                 | M3 | M6 | p   |
| Gender                                            |                 |    |    |     |
| Male                                              | 175/432 (40.5)  | 0.70 | 0.41 |      |
| Female                                            | 244/578 (42.2)  | 0.74 | 0.42 |      |
| Education                                         |                 |    |    |     |
| High school or lower                              | 178/451 (39.5)  | 0.71 | 0.39 |      |
| College or higher                                 | 241/560 (43.0)  | 0.73 | 0.43 |      |
| Marital status                                    |                 |    |    |     |
| Single/divorced/widowed/separated                 | 175/450 (38.9)  | 0.72 | 0.39 |      |
| Married/living as married                         | 244/561 (43.5)  | 0.72 | 0.43 |      |
| Age                                               |                 |    |    |     |
| < 25                                              | 5/18 (27.8)     | 0.78 | 0.28 |      |
| 25–39                                             | 102/264 (38.6)  | 0.69 | 0.39 |      |
| 40–55                                             | 141/345 (40.9)  | 0.70 | 0.41 |      |
| > 55                                              | 171/384 (44.5)  | 0.75 | 0.45 |      |
| Age                                               |                 |    |    |     |
| < 55                                              | 238/602 (39.5)  | 0.70 | 0.40 |      |
| ≥ 55                                              | 181/409 (44.3)  | 0.74 | 0.44 |      |
| Used cannabis 5 or more times in the last 12 months |               |    |    |     |
| No                                                | 245/580 (42.2)  | 0.73 | 0.42 |      |
| Yes                                               | 168/415 (40.5)  | 0.70 | 0.40 |      |
| Primary medical condition you currently treat with medical cannabis |               |    |    |     |
| Anxiety disorder                                  | 37/98 (37.8)    | 0.73 | 0.38 |      |
| Arthritis                                         | 27/63 (42.9)    | 0.75 | 0.43 |      |
| Cancer/leukemia                                   | 8/15 (53.3)     | 0.73 | 0.53 |      |
| Chronic pain                                      | 298/703 (42.4)  | 0.72 | 0.42 |      |
| Crohn’s disease                                   | 1/6 (16.7)      | 0.67 | 0.17 |      |
| Epilepsy                                          | 3/5 (60.0)      | 0.80 | 0.60 |      |
| Gastrointestinal disorder                         | 3/6 (50.0)      | 0.83 | 0.50 |      |
| Headache                                          | 8/23 (34.8)     | 0.78 | 0.35 |      |
| Insomnia                                          | 20/48 (41.7)    | 0.65 | 0.42 |      |
| Movement disorder                                 | 2/8 (25.0)      | 0.63 | 0.25 |      |
| PTSD                                              | 2/8 (25.0)      | 0.63 | 0.25 |      |
| Other                                             | 8/18 (44.4)     | 0.78 | 0.44 |      |
| Primary medical condition you currently treat with medical cannabis |               |    |    |     |
| Pain                                              | 333/789 (42.2)  | 0.72 | 0.42 |      |
| Mental health issues                              | 40/109 (36.7)   | 0.73 | 0.37 |      |
| Insomnia                                          | 20/48 (41.7)    | 0.65 | 0.42 |      |
| Other                                             | 26/64 (40.6)    | 0.77 | 0.41 |      |

M3 Month 3 timepoint, M6 Month 6 timepoint
Table 2  Percent completing M6 and probability of retention at M3 and M6 by baseline prescription drug use and quality of life (QOL) in 1011 participants

| Baseline prescription drug use and QOL | Completed M6 (%) | Kaplan–Meier estimator |
|----------------------------------------|------------------|------------------------|
|                                        |                  | Probability of remaining in study |
|                                        |                  | M3  | M6  | P   |
| **Use of opioid**                      |                  |     |     |     |
| No                                     | 306/697 (43.9)   | 0.74 | 0.44 | 0.004 |
| Yes                                    | 102/290 (35.2)   | 0.66 | 0.35 |     |
| **Opioid – defined daily dose (DDD)**  |                  |     |     |     |
| < 0.57                                 | 44/108 (40.7)    | 0.64 | 0.41 | 0.321 |
| ≥ 0.57                                 | 34/108 (31.5)    | 0.66 | 0.31 |     |
| **Use of non-opioid pain medications** |                  |     |     |     |
| No                                     | 314/770 (40.8)   | 0.73 | 0.41 | 0.721 |
| Yes                                    | 94/215 (43.7)    | 0.70 | 0.44 |     |
| **Non-opioid pain medications—defined daily dose (DDD)** | | | | 0.245 |
| < 0.43                                 | 37/76 (48.7)     | 0.72 | 0.49 |     |
| ≥ 0.43                                 | 36/89 (40.4)     | 0.64 | 0.40 |     |
| **Use of benzodiazepine**              |                  |     |     |     |
| No                                     | 375/918 (40.8)   | 0.71 | 0.41 | 0.151 |
| Yes                                    | 32/67 (47.8)     | 0.82 | 0.48 |     |
| **Benzodiazepine—defined daily dose (DDD)** | | | | 0.151 |
| < 0.38                                 | 13/29 (44.8)     | 0.71 | 0.41 |     |
| ≥ 0.38                                 | 15/27 (55.6)     | 0.82 | 0.48 |     |
| **Use of antidepressant**              |                  |     |     |     |
| No                                     | 324/818 (39.6)   | 0.71 | 0.40 | 0.011 |
| Yes                                    | 83/166 (50.0)    | 0.78 | 0.50 |     |
| **Antidepressant—defined daily dose (DDD)** | | | | 0.342 |
| < 1                                    | 14/35 (40.0)     | 0.74 | 0.40 |     |
| ≥ 1                                    | 45/90 (50.0)     | 0.78 | 0.50 |     |
| **Use of anti-seizure**                |                  |     |     |     |
| No                                     | 326/827 (39.4)   | 0.71 | 0.39 | 0.003 |
| Yes                                    | 83/159 (52.2)    | 0.79 | 0.52 |     |
| **Anti-seizure—defined daily dose (DDD)** | | | | 0.542 |
| < 0.5                                  | 24/46 (52.2)     | 0.80 | 0.52 |     |
| ≥ 0.5                                  | 34/72 (47.2)     | 0.75 | 0.47 |     |
| **WHOQOL—physical health (baseline)**  |                  |     |     |     |
| < 36                                   | 218/526 (41.4)   | 0.74 | 0.41 | 0.671 |
| ≥ 36                                   | 199/481 (41.4)   | 0.70 | 0.41 |     |
| **WHOQOL—psychological (baseline)**    |                  |     |     |     |
| < 54                                   | 166/442 (37.6)   | 0.71 | 0.38 | 0.042 |
| ≥ 54                                   | 251/565 (44.4)   | 0.73 | 0.44 |     |
| **WHOQOL—social relationships (baseline)** | | | | 0.168 |
| < 58                                   | 147/384 (38.3)   | 0.71 | 0.38 |     |
| ≥ 58                                   | 270/623 (43.3)   | 0.72 | 0.43 |     |
| **WHOQOL—environment (baseline)**      |                  |     |     |     |
| < 66                                   | 222/556 (39.9)   | 0.70 | 0.40 | 0.166 |
| ≥ 66                                   | 195/451 (43.2)   | 0.75 | 0.43 |     |

M3 = month 3 timepoint, M6 = month 6 timepoint
This was also reflected in the lower probability of people reporting opioid use remaining in the study at M3 and M6 (66% at M3 and 35% at M6 for opioid users compared to 74% and 44% for non-opioid users; \( p = 0.004 \)). However, the use of antidepressants and of anti-seizure drugs were both associated with greater percentage of M6 completion, and associated increases in probability of retention at M3 and M6. Probability of retention at M3 and M6 for those using antidepressants was 78% and 50%, respectively, compared to 71% at M3 and 40% at M6 for those not using antidepressants \( (p = 0.011) \). Those using anti-seizure medications saw similar outcomes: 79% (M3) and 52% (M6) compared to 71% and 39% for non-users \( (p = 0.003) \).

For quality of life, median baseline scores were used to create a binary comparison, and only a higher baseline score for the psychological measure of WHOQOL-Bref was associated with increased probability of remaining in the study. Those scoring 54 or better had a 73% probability of remaining in the study at M3, and 44% at M6, compared to 71% at M3 and 38% at M6 for those who scored below 54 \( (p = 0.042) \).

Table 3 highlights the rate of study completion and probability of retention at M3 and M6 by baseline medical cannabis use. Median weekly cannabis use was 5.0 g (IQR 2.0–7.5). In regard to preferred types of cannabis products, the most cited was high CBD (461, 46.8%), and more patients cited “no preference” (286, 29%) than those who identified a preference for THC (239, 24.2%). For primary method of use, oral ingestion was cited by 546 (54.7%) while inhaled methods (e.g., vaporizers, joints, pipes, and bongs) accounted for 44.6%. Additionally, most participants reported using at least some extract (orally ingested) products (619, 61.9%).

Citing no preference for either THC or CBD significantly increased the probability of retention at M6 (49% for no preference vs. 44% for THC and 38% for CBD, \( p = 0.044 \)), as did inhalation vs. oral ingestion (46% for inhalation vs. 38% for oral ingestion, \( p = 0.027 \)). However, this analysis found no association between the amount of cannabis used per week, frequency of use per week, and

### Table 3

| Baseline cannabis use | Completed M6 (%) | Kaplan–Meier estimator |
|-----------------------|-----------------|------------------------|
|                       | Probability of remaining in study | M3 | M6 | \( P \) |
| **Cannabis use per week (g)** | | | | |
| \(< 5\) | 211/495 (42.6) | 0.74 | 0.43 | 0.567 |
| \(\geq 5\) | 208/505 (41.2) | 0.72 | 0.41 | |
| **Frequency of cannabis use per week** | | | | |
| \(< 14\) | 186/428 (43.5) | 0.72 | 0.43 | 0.587 |
| \(\geq 14\) | 233/571 (40.8) | 0.73 | 0.41 | |
| **Currently using Tilray extract products** | | | | |
| No | 165/381 (43.3) | 0.71 | 0.43 | 0.751 |
| Yes | 254/619 (41.0) | 0.74 | 0.41 | |
| **Preferred type of cannabis** | | | | 0.044 |
| THC | 105/239 (43.9) | 0.72 | 0.44 | |
| High CBD | 174/461 (37.7) | 0.73 | 0.38 | |
| No preference | 139/286 (48.6) | 0.74 | 0.49 | |
| **Primary method of use** | | | | \(<0.001\) |
| Vaporizer—cannabis flower | 99/167 (59.3) | 0.80 | 0.59 | |
| Vaporizer/nail—cannabis extracts | 2/10 (20.0) | 0.50 | 0.20 | |
| Joint | 73/194 (37.6) | 0.71 | 0.38 | |
| Oral | 209/546 (38.3) | 0.72 | 0.38 | |
| Pipe | 11/33 (33.3) | 0.58 | 0.33 | |
| Waterpipe/bong | 18/35 (51.4) | 0.80 | 0.51 | |
| Topical | 5/11 (45.5) | 0.82 | 0.45 | |
| **Primary method of use** | | | | 0.027 |
| Inhaled | 203/439 (46.2) | 0.74 | 0.46 | |
| Orally ingested | 209/546 (38.3) | 0.72 | 0.38 | |

*M3 = month 3 timepoint, M6 = month 6 timepoint*
Table 4  Unadjusted odds of completing M6 in 1011 participants by baseline patient characteristics and other variables

| Patient characteristics                                      | Univariate analysis |         |         |         |
|--------------------------------------------------------------|---------------------|---------|---------|---------|
|                                                              | OR\(^a\)            | 95% CI\(^b\) | P       |         |
| **Gender**                                                   |                     |         |         |         |
| Female                                                       | —                   | —       | —       | —       |
| Male                                                         | 0.93                | 0.72, 1.20 | 0.587  |         |
| **Education**                                                |                     |         |         |         |
| College or lower                                             | —                   | —       | —       | —       |
| High school or lower                                         | 0.86                | 0.67, 1.11 | 0.252  |         |
| **Marital status**                                           |                     |         |         |         |
| Married/living as married                                    | —                   | —       | —       | —       |
| Single/divorced/widowed/separated                            | 0.83                | 0.64, 1.06 | 0.140  |         |
| **Age**                                                      |                     |         |         |         |
| < 55                                                         | —                   | —       | —       | —       |
| ≥ 55                                                        | 1.21                | 0.94, 1.57 | 0.135  |         |
| **Used cannabis for any reason 5 or more times in the last 12 months** |                     |         |         |         |
| No                                                           | —                   | —       | —       | —       |
| Yes                                                          | 0.93                | 0.72, 1.20 | 0.579  |         |
| **Primary illness or medical condition you currently treat with medical cannabis** |                     |         |         |         |
| Pain                                                         | —                   | —       | —       | —       |
| Mental health issues                                         | 0.79                | 0.52, 1.20 | 0.275  |         |
| Insomnia                                                     | 0.98                | 0.54, 1.77 | 0.942  |         |
| Other                                                        | 0.94                | 0.56, 1.57 | 0.805  |         |
| **Use of opioid**                                            |                     |         |         |         |
| N                                                            | —                   | —       | —       | —       |
| Y                                                            | 0.69                | 0.52, 0.92 | 0.011  |         |
| **Use of non-opioid pain medications**                       |                     |         |         |         |
| N                                                            | —                   | —       | —       | —       |
| Y                                                            | 1.13                | 0.83, 1.53 | 0.439  |         |
| **Use of benzodiazepine**                                    |                     |         |         |         |
| N                                                            | —                   | —       | —       | —       |
| Y                                                            | 1.32                | 0.81, 2.18 | 0.269  |         |
| **Use of antidepressant**                                   |                     |         |         |         |
| N                                                            | —                   | —       | —       | —       |
| Y                                                            | 1.52                | 1.09, 2.13 | 0.014  |         |
| **Use of anti-seizure**                                      |                     |         |         |         |
| N                                                            | —                   | —       | —       | —       |
| Y                                                            | 1.68                | 1.19, 2.36 | 0.003  |         |
| **Opioid—dose per day (DDD)**                                |                     |         |         |         |
| >0, <0.57                                                    | —                   | —       | —       | —       |
| ≥0.57                                                       | 0.67                | 0.38, 1.17 | 0.157  |         |
| **Non-opioid pain medications—dose per day (DDD)**           |                     |         |         |         |
| >0, <0.43                                                    | —                   | —       | —       | —       |
| ≥0.43                                                       | 0.72                | 0.39, 1.33 | 0.289  |         |
| **Benzodiazepine—dose per day (DDD)**                        |                     |         |         |         |
| >0, <0.38                                                    | —                   | —       | —       | —       |
| ≥0.38                                                       | 1.54                | 0.54, 4.42 | 0.423  |         |
| **Antidepressant—dose per day (DDD)**                        |                     |         |         |         |
| >0, <1                                                      | —                   | —       | —       | —       |
| ≥1                                                          | 1.50                | 0.68, 3.31 | 0.316  |         |
reporting use of extract products, and the probability of retention at M3 or M6.

Table 4 presents the results of the univariate logistic regression as the unadjusted odds of completing M6 by baseline patient characteristics and other variables of interest, including the legalization of non-medical adult use of cannabis in Canada. Overall, primary patient characteristics such as gender, education, marital status, age, previous experience with cannabis, and primary condition were not found to be associated with retention. However, baseline prescription drug use, quality of life, aspects of cannabis use, and cannabis legalization were associated with significant impacts on the odds of completing M6 (Table 4).

Using opioids was associated with lower unadjusted odds of completing the study ($p=0.011$), and this outcome appeared to be independent of the daily dose used by participants. Conversely, patients using antidepressants had greater odds of retention ($p=0.014$), as did those using anti-seizure medication ($p=0.003$); however, as with opioids, these outcomes were not associated with specific defined daily doses. In regard to baseline quality

### Table 4 (continued)

| Patient characteristics | Univariate analysis |
|-------------------------|---------------------|
|                         | OR$^a$   | 95% CI$^b$ | $P$    |
| **Anti-seizure—dose per day (DDD)** |
| $>0, <0.5$               | —       | —         | —      |
| $\geq 0.5$               | 0.82    | 0.39, 1.72 | 0.60   |
| **WHOQOL—physical health (baseline)** |
| $<36$                    | —       | —         | —      |
| $\geq 36$                | 1       | 0.78, 1.28 | 0.981  |
| **WHOQOL—psychological (baseline)** |
| $<54$                    | —       | —         | —      |
| $\geq 54$                | 1.33    | 1.03, 1.71 | 0.028  |
| **WHOQOL—social relationships (baseline)** |
| $<58$                    | —       | —         | —      |
| $\geq 58$                | 1.23    | 0.95, 1.60 | 0.114  |
| **WHOQOL—environment (baseline)** |
| $<66$                    | —       | —         | —      |
| $\geq 66$                | 1.15    | 0.89, 1.47 | 0.289  |
| **Cannabis use per week (g)** |
| $<5$                     | —       | —         | —      |
| $\geq 5$                 | 1.06    | 0.83, 1.36 | 0.645  |
| **Frequency of cannabis use per week** |
| $<14$                    | —       | —         | —      |
| $\geq 14$                | 1.11    | 0.87, 1.44 | 0.401  |
| **Currently using Tilray extract products** |
| N                        | —       | —         | —      |
| Y                        | 0.91    | 0.70, 1.18 | 0.479  |
| **Preferred type of cannabis** |
| CBD                      | —       | —         | —      |
| THC                      | 1.29    | 0.94, 1.78 | 0.113  |
| No preference            | 1.56    | 1.16, 2.10 | 0.004  |
| **Primary method of use** |
| Inhaled                  | —       | —         | —      |
| Orally ingested          | 0.72    | 0.56, 0.93 | 0.012  |
| **Enrollment period**    |
| Enrolled prior to 17 April 2018 (M6 would be pre-legalization) | —       | —         | —      |
| Enrolled between 17 April and 15 July 2018 (M6 would be post legalisation) | 0.32    | 0.22, 0.46 | <0.001  |

$^a$OR: Odds ratio, $^b$CI: Confidence interval
of life as measured by WHOQOL-Bref, a score of 54 or more in the psychological domain was associated with greater odds of retention compared to those scoring below 54 ($p = 0.028$). None of the other three domains assessed—physical health, social relationships, or environment—appeared to be associated with retention.

Specific to cannabis use, citing no preference for either THC or CBD was associated with greater odds of retention compared to citing a preference for CBD, while a preference for THC was not associated with retention ($p = 0.113$). Moreover, using cannabis via oral ingestion was found to result in lower odds of completing M6 compared to those who inhale cannabis as their primary method of use ($p = 0.012$).

Finally, cannabis legalization was found to have a significant impact on retention at M6. Participants who enrolled in the study in the period that would have resulted in M6 being after legalization had significantly lower odds of completing the study than those who enrolled prior to that period ($p < 0.001$).

Table 5 presents the results of a multivariate model that included all variables found to be significant in the univariate analyses. The primary factor impacting retention was legalization (AOR = 0.28, 95% CI 0.18–0.41). Additionally, the use of opioids continued to be significantly associated with reductions in the adjusted odds of retention at M6 (AOR = 0.62, 95% CI 0.46–0.85). Moreover, the use of anti-seizure medications continued to be associated with significantly greater adjusted odds of retention at M6 (AOR = 1.91, 95% CI 1.08–1.90), as was WHOQOL-Bref psychological scores of $\geq 54$ (AOR = 1.43, 95% CI 1.08–1.90), with both associations actually increasing in the multivariate model. However, this analysis also found that the use of antidepressants was no longer associated with retention ($p = 0.061$), nor was using a specific primary method of use, citing a preference for THC or CBD, or citing no preference for either.

### Discussion

In this study, we found that non-medical cannabis legalization was independently associated with retention in the Tilray Observational Patient Survey. Additionally, the survival analysis and subsequent logistic regressions identified specific participant characteristics that were associated with the percentage, probability, and adjusted odds of retention at M6. Specifically, the use of opioids was strongly associated with greater probability and adjusted odds that participants would be LTFU before

| Table 5 Adjusted odds of remaining in the study at M6 by variables found to be significant in univariate regression analysis |
|---------------------------------------------------------------|
| Significant variables                                      | Multivariate regression analysis |
|                                                             | AOR$^a$ | 95% CI$^b$ | $P$    |
| Use of opioid                                               |         |            |       |
| N                                                            | —       | —          |       |
| Y                                                            | 0.62    | 0.46, 0.85 | 0.003 |
| Use of antidepressant                                       |         |            |       |
| N                                                            | —       | —          |       |
| Y                                                            | 1.42    | 0.98, 2.07 | 0.061 |
| Use of anti-seizure                                         |         |            |       |
| N                                                            | —       | —          |       |
| Y                                                            | 1.91    | 1.30, 2.81 | <0.001|
| WHOQOL—psychological (baseline)                             |         |            |       |
| $< 54$                                                       | —       | —          |       |
| $\geq 54$                                                   | 1.43    | 1.08, 1.90 | 0.013 |
| Preferred type of cannabis                                  |         |            |       |
| CBD                                                         | —       | —          |       |
| THC                                                         | 0.87    | 0.59, 1.27 | 0.5   |
| No preference                                               | 1.16    | 0.82, 1.63 | 0.4   |
| Primary method of use                                       |         |            |       |
| Inhaled                                                     | —       | —          |       |
| Orally ingested                                             | 0.87    | 0.64, 1.19 | 0.4   |
| Enrollment period                                           |         |            |       |
| Enrolled prior to 17 April 2018 (M6 would be pre-legalization)| —       | —          |       |
| Enrolled between 17 April and 15 July 2018 (M6 would be post-legalization)| 0.28    | 0.18, 0.41 | <0.001|

$^a$ AOR Adjusted odds ratio, $^b$ CI Confidence interval
completing the study, while a higher baseline psychological score and the use of anti-seizure medications and were both associated with increased retention at M6.

The finding that the adjusted odds of participants being LTFU were three-fold higher compared to the pre-legalization period is consistent with other data examining the impacts of legalization on medical cannabis access in Canada. National polling data from January 2019 that included over 800 adult Canadian medical cannabis patients found that 26% of patients reported that medical cannabis had become more difficult to access since legalization, and that 48% of patients polled accessed cannabis via the illegal market, while 44% accessed cannabis via the legal non-medical market (Abacus 2019). Furthermore, a study of Canadian cancer patients that compared medical cannabis access and use both before ($n = 821$) and after legalization ($n = 852$) cited significant challenges obtaining cannabis products post-legalization (Hawley 2020). News reports from that time and subsequent academic studies suggest that industry-wide shortages of both legal medical and non-medical cannabis products likely resulted from the emergence of novel licensed retail outlets and online sales channels and the associated increase in demand, which diluted the available legal supply to both medical and non-medical markets channels (Armstrong 2019a, b, 2021). The lack of authorized cannabis products in the months immediately following legalization led Ontario, Canada’s most populous province, to temporarily halt the licensing of legal storefront dispensaries (Armstrong 2019b; Mazur 2019). News reports suggest this shortage lasted for many months, and likely led to a diversion of medical and non-medical cannabis consumers to access via illicit channels (Armstrong 2019a). While there were no measures in this study assessing whether patients LTFU in TOPS left the care of the participating clinics, stopped using medical cannabis, or simply accessed it from alternative sources, it is reasonable to presume that policy changes having a national impact on legal access to medical cannabis in Canada would also affect authorized patients involved in prospective medical cannabis studies over the same period, and that the reported product shortages provide a rationale for the significant decrease in retention seen in TOPS post-legalization.

While the supply situation appears to have been rectified, data from Health Canada highlights an 18% decline in patients registered in the federal medical cannabis program between September 2019 and June 2020 (the latest available data at the time of writing), suggesting the patient migration away from the federal medical cannabis program may be a longer-term trend (Health Canada 2020). That same period saw a steady expansion of regulated community-based non-medical retail outlets offering a large selection of different products at prices that are often lower than those in the legal medical market, which stands in sharp contrast to the online-only medical cannabis market that many patients have long complained is too expensive and difficult to access (Belle-Îsle et al. 2014; Capler et al. 2017; Valerian et al. 2020). However, there are some policy options the federal government could consider that might address some of the perceived shortcomings of the federal medical cannabis program, including allowing pharmacy-based access, which would have the important ancillary benefit of increased engagement with health care providers, since pharmacists could provide in-person information about safe use, adverse events, and potential contraindications. Additionally, reducing the cost of medical cannabis by extending the tax-exempt status of other prescription medicines in Canada to all medical cannabis products, and/or by expanding opportunities for cost coverage via private or public payers could also incentivize patients to access cannabis products via the medical system, as has been the case in Germany (Pascual 2020), thereby reducing the odds that patients enrolled in prospective medical cannabis studies would opt out of the federal medical cannabis program and subsequently be LTFU.

The outcomes of this study also suggest that patient capacity and study burden may have impacted retention. While only a few variables were shown to be associated with adjusted odds of retention at M6, most seem to be consistent with characteristics that may be indicative of overall patient physical/psychological capacity. Primarily, the finding that baseline opioid use reduced survival/retention in the TOPS study could be reflective of a patient population with less stable physical and psychological health conditions sometimes associated with or resulting from chronic opioid therapy (Baldini et al. 2012; Dobscha et al. 2013; Sullivan 2018), and which research has shown may impact retention in prospective studies (Zweben et al. 2009; O’Connor et al. 2020). Similarly, the finding that having a higher baseline score for the psychological measure of WHOQOL-Bref was associated with increased odds of retention further suggests that patient psychological capacity may have been a significant internal factor affecting the odds of patients being LTFU in TOPS. The only relevant finding that appeared unrelated to patient physical or psychological capacity was that the use of anti-seizure medications was associated with greater odds of retention. This outcome may be reflective of the well-established relationship between treatment adherence, reduced seizure frequency and severity, and improved quality of life in patients affected by seizure disorder (Sancho et al. 2010; Lin et al. 2016; Hamedi-Shahraki et al. 2019), which may have increased the motivation of this particular patient cohort to continue using
cannabis within the scope of the federal medical cannabis program, and to subsequently remain in the study as well.

While recruiting participants with greater capacity could improve retention in future medical cannabis studies, it might also lead to recruitment bias and ultimately confound findings. Additionally, since such a significant portion of medical cannabis patients also use opioids (Campbell et al. 2018; Chen et al. 2019; Lucas et al. 2019; Safakish et al. 2020), it would be hard to justify excluding these patients from future research. Therefore, a better option to improve retention would be find ways to reduce study burden on this vulnerable patient population. Studies and systematic reviews specifically examining retention in prospective studies have found that study burden is one of the most significant factors affecting the odds of patients being LTFU, and have identified a number of barrier-reduction strategies that can significantly increase retention (Kearney et al. 2017; Sommer et al. 2018; Teague et al. 2018; Naidoo et al. 2020). These include reducing the number of study visits and associated assessments, improving patient compensation, and providing flexibility in data collection methods such as conducting follow-ups via web-based surveys, phone, or telemedicine (Zweben et al. 2009; Abshire et al. 2017; Svendsen et al. 2017; Teague et al. 2018).

This study has a number of strengths and limitations. This was a convenience sample recruited at 21 medical clinics across 5 Canadian provinces, and although the primary patient characteristics are consistent with similar studies of medical cannabis patient populations in Canada, Europe, Australia, and the USA (Hazekamp et al. 2013; Baron et al. 2018; Boehnke et al. 2019; Lintzeris et al. 2020), there is no guarantee this sample is representative of the general Canadian medical cannabis patient population, thereby limiting the generalizability of these findings. Since many of the clinics specialize in the treatment of chronic pain, there may be an over-representation of patients affected by chronic pain. Data regarding the use of cannabis was self-reported by patients and did not benefit from biological drug detection to confirm use or non-use of cannabis, so is subject to potential recall bias.

These limitations are counterbalanced by several methodological strengths, including the large number of participants (to the best of our knowledge this is the largest national prospective survey of Canadian medical cannabis patients to date), gathering of highly detailed data on patterns of cannabis and prescription drug use, and data entry of prescription drug use by physicians, rather than relying on patient self-report.

Conclusions
Cannabis legalization in Canada has successfully shifted the regulation of cannabis from a predominantly criminal justice approach to one focused on public health and harm reduction. However, an ancillary and perhaps unexpected outcome has been its subsequent impact on patient access to medical cannabis, and associated efforts to study this population. While this analysis cannot determine if the association between legalization and reduced odds of retention in TOPS is unique to this study and/or the period immediately following legalization or indicative of a broader trend, researchers conducting prospective studies on cannabis in Canada and around the globe should anticipate and attempt to mitigate the potential impacts of increased access options on study retention. Evidence-based barrier reduction strategies that could reduce the odds of patients being lost to follow-up include minimizing the number of study visits and assessments, ensuring adequate patient compensation, and conducting follow-ups via online surveys, phone-based interviews, and telemedicine. Should increased access options continue to erode patient participation in Canada’s federal medical cannabis program and subsequently in studies assessing the harms and benefits of medical cannabis, pragmatic policy solutions designed to better meet the needs of patients—such as pharmacy-based access and increased cost-coverage—could form part of a more comprehensive strategy to improve patient access to medical cannabis and improve retention in prospective studies of this population.

Abbreviations
AOR: Adjusted odds ratio; CBD: Cannabidiol; CI: Confidence interval; CUS: Cannabis Use Survey; DDD: Defined daily dose; LTFU: Lost to follow-up; M1: Month 1 data point; M3: Month 3 data point; M6: Month 6 data point; MME: Morphine milligram equivalent; NDDF: National Drug Data File; OR: Odds ratio; p: p value; PQD: Prescription Drug Questionnaire; QOL: Quality of life; THC: Tetrahydrocannabinol; TOPS: Tilray Observational Patient Study; VAS: Visual assessment scale; WHOQOL-Bref: World Health Organization Quality of Life Short Form.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s42238-021-00089-7.

Additional file 1. TOPS Health Care Provider Talking Points.

Acknowledgements
The authors would like to thank all of the patients who shared their experiences, the health care providers, and clinics for their commitment of time and resources, and Tilray for funding this study. We would also like to thank Sunny Razzagh for assisting with clinic recruitment, and Terry Lee and Joel Singer from the Centre for Health Evaluation Outcome Sciences (CHEOS) and Scott Emerson from Broadstreet for their skilled assistance with the analysis of this data.
Institutes of Health Research (CIHR) and a Scholar Award from the Michael Smith Foundation for Health Research. This study was funded by Tilray, a federally authorized Canadian medical cannabis production and research company, during the study. SB has no competing financial interests. MJM has no competing financial interests. ZW has also received unstructured funding from NG Biomed, Ltd., an applicant for authorization. medical cannabis production and research company, during the study. SB has no competing financial interests. MJM has no competing financial interests. ZW has also received unstructured funding from NG Biomed, Ltd., an applicant for authorization. medical cannabis production and research company.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was reviewed and approved by Advarra (formerly Institutional Review Board Services) on 22 January 2016, the University of Victoria on 7 April 2016 (#16-059), and the Alberta Health Research Ethics Board of Alberta 3 October 2016 (HREA/CHC160019). Tilray was the study sponsor and participated in the design of the study, along with co-investigators from the University of British Columbia and University of Victoria. All data gathering was conducted by health care providers and medical staff in clinic, and analysis was conducted at arms length by the Centre for Health Evaluation Outcome Sciences at UBC and Broadstreet.

Consent for publication
Not applicable.

Competing interests
PL was Vice-President, Global Patient Research and Access for Tilray, an authorized. medical cannabis production and research company, during this study. SB has no competing financial interests. MJM has no competing financial interests. He is supported by the United States. National Institutes of Health (U01-DA0251525), a New Investigator Award from the Canadian Institutes of Health Research (CIHR) and a Scholar Award from the Michael Smith Foundation for Health Research (MSFHR). M-JM is the Canopy Growth professor of cannabis science at the University of British Columbia (UBC), a position created using unstructured arms' length gifts to the university from Canopy Growth Corporation, a licensed producer of cannabis, and the Government of British Columbia's Ministry of Mental Health and Addictions. UBC has also received unstructured funding from NG Biomed, Ltd., an applicant to the Canadian federal government for a license to produce cannabis, to support MJM. ZW is the Primary Investigator in a Tilray-sponsored randomized clinical trial of medical cannabis and PTSD, and has also received research funding from DOJ's licensed producer of cannabis; he receives no financial compensation from Tilray or DOJ. ZW is also a Director of Indigenous Bloom Corporation which works to establish opportunities for Canadian Indigenous groups to engage in the cannabis industry. He has been compensated for his work with shares in Indigenous Bloom.

Author details
1 Social Dimensions of Health, University of Victoria, 3800 Finnerty Rd, Victoria, B.C.V8P 5C2, Canada. 2 1100 Maughan Rd, Nanaimo, BC V9X1J2, Canada. 3 Canadian Institute for Substance Use Research, 2300 McKenzie Ave, Victoria, BC V8N 5M8, Canada. 4 Faculty of Human and Social Development, School of Public Health and Social Policy, University of Victoria, 3800 Finnerty Rd, Victoria, B.C. V8P 5C2, Canada. 5 Faculty of Medicine, University of British Columbia, St. Paul's Hospital, Burrard Street, Vancouver, B.C. 806-1081, Canada. 6 British Columbia Centre On Substance Use, 400-1045 Howe St, Vancouver, B.C V6Z 2A9, Canada. 7 Department of Psychology, University of British Columbia, 3333 University Way, Okanagankelowna, B.C V1V 1V7, Canada. 8 Centre for the Advancement of Psychological Science and Law, University of British Columbia, 3333 University Way, Okanagankelowna, BC V1V 1V7, Canada.

Received: 4 December 2020   Accepted: 9 July 2021
Published online: 28 July 2021

References
Abacus, C.P Canada. Medical Cannabis Study. Ottawa: Medical Cannabis Users, 2019.
Abshire M, Dinglas VD, Cajita MA, et al. Participant retention practices in longitudinal clinical research studies with high retention rates. BMC Med Res Methodol. 2017;17:30. https://doi.org/10.1186/s12874-017-0310-z.
Armstrong M. Canada is a tale of two cannabis shortages - The Globe and Mail. Globe Mail. 2019a.
Armstrong P. Canada’s chronic shortage of legal cannabis expected to drag on for years | CBC News. CBC News. 2019b.
Armstrong MJ. Legal cannabis market shares during Canada’s first year of recreational legalization. Int J Drug Policy. 2021;88:103028. https://doi.org/10.1016/j.drugpo.2020.103028.

Baldini A, von Korff M, Lin EHB. A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. Prim. Care Companion J Clin Psychiatry. 2012;14(3). https://doi.org/10.4088/PCC.11m01326.

Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018;19:37. https://doi.org/10.1186/s10194-018-0862-2.

Belle-Isle L, Hathaway A. Barriers to access to medical cannabis for Canadians living with HIV/AIDS. AIDS Care. 2007;19:500–6. https://doi.org/10.1080/09540120701207833.

Belle-Isle L, Walsh Z, Callaway R, et al. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy. 2014;25:691–9. https://doi.org/10.1016/j.drugpo.2014.02.009.

Boehnke KF, Scott JR, Littias E, et al. Pills to pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J Pain. 2019;20:830–41. https://doi.org/10.1016/j.jpain.2019.01.010.

Bonaccorso S, Ricciardi A, Zangani C, et al. Cannabidiol (CBD) use in psychiatric disorders: a systematic review. Neurotoxicology. 2019;74:282–98.

Bottorff JL, Bissell LJL, Balbeaves LG, et al. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J. 2013;10:2. https://doi.org/10.1186/1477-7517-10-2.

Campbell G, Hall WD, Peacock A, et al. Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. Lancet Public Heal. 2018;3:e341–50. https://doi.org/10.1016/S2468-2667(18)30110-5.

Health Canada. Data on cannabis for medical purposes – Canada.ca. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/medical-purpose.html#a1. Accessed 4 Nov 2020

Cannabis | CMA Health Topics. https://www.cma.ca/cannabis. Accessed 16 Sep 2020

Caperl R, Walsh Z, Crosby K, et al. Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. Int J Drug Policy. 2017;47:1–8. https://doi.org/10.1016/j.drugpo.2017.05.046.

Chen X, Cowan A, Innan S, et al. Opioid-sparing effects of cannabinoids on morphine analgesia: participation of CB1 and CB2 receptors. Br J Pharmacol. 2019;176:3378–89. https://doi.org/10.1111/bph.14769.

Dobcsa SK, Morasco B, Duckart JP, et al. Correlates of prescription opioid initiation and long-term opioid use in veterans with persistent pain. Clin J Pain. 2013;29:102–8. https://doi.org/10.1097/AJP.0b013e3182490d6b.

Fischer B, Lee A, O'Keefe-Markman C, Hall W. Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. EClinical-Medicine. 2020;20:100294.

Geary A. Regulations, funding keep Canada from becoming world leader in cannabis research, scientists say: CBC News, 2019. In: CBC News. https://www.cbc.ca/news/canada/montana/canada-cannabis-research-barriers-1.5326667. Accessed 29 Sep 2020

Hamed-Shahriari S, Eshraghian MR, Yekaninejad MS, et al. Health-related quality of life and medication adherence in elderly patients with epilepsy. Neurof Neurochir Pol. 2019;53:123–30. https://doi.org/10.5603/PNNS.a20190008.

Harris PA. AMA applauds Surgeon General’s advisory on cannabis | American Medical Association, 2019. In: AMA Statements. https://www.ama-assn.org/press-center/ama-statements/ama-applauds-surgeon-general-s-advisory-cannabis. Accessed 16 Sep 2020
Harris PA, Taylor R, Thielke R, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2009;42:377–81. https://doi.org/10.1016/j.jbi.2008.08.010.

Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.

Hawley PH, Gobbo M, Aghani N. The impact of legalisation of access to recreational Cannabis on Canadian medical users with cancer. BMC Health Serv Res. 2020 Oct 27;20(1):977. https://doi.org/10.1186/s12913-020-05756-8.

Hazeckamp A, Ware M, a, Muller-Vahl K., et al. The medicinal use of cannabis and cannabinoids—An international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199–210. https://doi.org/10.1080/02791072.2013.805976.

Hoch E, Niemann D, von Keller R, et al. How effective and safe is medical cannabis as a treatment for mental disorders? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269:87–105.

Kearney A, Daykin A, Shaw ARG, et al. Identifying research priorities for effective retention strategies in clinical trials. Trials. 2017;18:406. https://doi.org/10.1186/s13063-017-2132-2.

Kosiba JD, Maisto SA, Ditre JW. Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis. Soc Sci Med. 2019;233:181–92.

Lin CY, Chen H, Pakpour AH. Correlation between adherence to antiepileptic drugs and quality of life in patients with epilepsy: A longitudinal study. Epilepsy Behav. 2016;63:103–8. https://doi.org/10.1016/j.yebeh.2016.07.042.

Lintzeris N, Lintzeris N, Mills L, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;17:37. https://doi.org/10.1186/s12916-020-00377-0.

Lucas P. Moral regulation and the presumption of guilt in Health Canada’s medical cannabis policy and practice. Int J Drug Policy. 2009;20:296–303. https://doi.org/10.1016/j.drugpo.2008.09.007.

Lucas P, Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy. 2017;42:30–5. https://doi.org/10.1016/j.drugpo.2017.01.011.

Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):9.

Mazur A. Canada’s cannabis supply issues are real, despite feds’ denial, says business professor. Globalnews.ca, 2019. Glob. News. https://globalnews.ca/news/5673653/canadas-cannabis-supply-feds-denial/. Accessed 26 Jul 2021.

McTaggart-Cowan H, Bentley C, Raymakers A, et al. Understanding cancer survivors’ reasons to medicate with cannabis: a qualitative study based on the theory of planned behavior. Cancer Med. 2020. https://doi.org/10.1002/cam4.3535.

Naidoo N, Nguyen VT, Ravaud P, et al. The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence. BMC Med. 2020;18:6. https://doi.org/10.1186/s12916-019-1476-6.

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 Jan 12. 15, Challenges and Barriers in Conducting Cannabis Research. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425757/.

O’Connor AM, Cousins G, Durand J, et al. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020;15:e0232086.

Okusanya BO, Asaolu IO, Ehiri JE, et al. Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review. Syst Rev. 2020;9:167.

Pascual A. Insurance reimbursement for German medical marijuana record. Marijuana Bus. Dly. 2020. https://mjbizdaily.com/insurance-covered-cannabis-in-germany-sets-fourth-quarter-record-push-pushing-2019-total-to-123-million-euros/. Accessed 4 Nov 2020

Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol. 2016;7:309. https://doi.org/10.3389/fphar.2016.00309.

Safakish R, Ko G, Salimpour V, et al. Medical cannabis for the management of pain and quality of life in chronic pain patients: a prospective observational study. Pain Med. 2020;21:3073–86. https://doi.org/10.1093/pm/pnaa163.

Sancho J, Iváñez V, Molins A, et al. Changes in seizure severity and quality of life in patients with refractory partial epilepsy. Epilepsy Behav. 2010;19:409–13. https://doi.org/10.1016/j.eyebeh.2010.08.011.

Saxena S, Carlson D, Billington R. The WHO quality of life assessment instrument (WHOQOL-Bref): the importance of its items for cross-cultural research. Qual Life Res. 2001;10:711–21.

Sommer C, Zuccolin D, Arnera V, et al. Building clinical trials around patients: evaluation and comparison of decentralized and conventional site models in patients with low back pain. Contemp Clin Trials Commun. 2018;11:120–6. https://doi.org/10.1016/j.cctc.2018.06.008.

Sullivan MD. Depression effects on long-term prescription opioid use, abuse, and addiction. Clin J Pain. 2018;34:878–84. https://doi.org/10.1097/AJP.0000000000000603.

Svendsen TS, Erga AH, Hagen E, et al. How to maintain high retention rates in long-term research on addiction: a case report. J Soc Work Prac Addict. 2017;17:374–87. https://doi.org/10.1080/1533256X.2017.1361831.

Teague S, Youssef GI, Macdonald JA, et al. Retention strategies in longitudinal cohort studies: a systematic review and meta-analysis. BMC Med Res Methodol. 2018;18:151. https://doi.org/10.1186/s12874-018-0585-7.

Valleriani J, Haines-Saah R, Capler R, et al. The emergence of innovative cannabis distribution projects in the downtown eastside of Vancouver, Canada. Int J Drug Policy. 2020;79:102737. https://doi.org/10.1016/j.drugpo.2020.102737.

Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24:511–6. https://doi.org/10.1016/j.drugpo.2013.08.010.

WHO Collaboration Center for Drug Statistics Methodology. WHOCC - ATC/DDD Index 2019. https://www.whocc.no/atc_ddd_index/. Accessed 16 Jul 2019.

Zweben A, Fucito LM, O’malley SS. Effective strategies for maintaining research participation in clinical trials. Ther Innov Regul Sci. 2009;43:459–67. https://doi.org/10.1177/02981509093400411.